研究目的
To determine the optical coherence tomography (OCT) parameters that are predictive of visual outcome after anti-VEGF therapy for a retinal vein occlusion (RVO).
研究成果
Eyes with severe ME before the treatment or with outer retinal impairments at the time of ME resolution had worse visual outcome after anti-VEGF therapy for RVO. Among the OCT parameters, the pretreatment MV was a strong predictive factor for the visual outcome after anti-VEGF therapy.
研究不足
The sample size was relatively small, and the follow-up period was relatively short. The study included patients with BRVO and those with CRVO, and both patients treated with bevacizumab and those with ranibizumab. The present study did not evaluate the degree of ischemic changes.
1：Experimental Design and Method Selection:
Fifty-seven eyes with macular edema (ME) secondary to a central or branch RVO treated with bevacizumab or ranibizumab were studied. Spectral-domain OCT and microperimetry were performed before, 1, 3, and 6 months after the treatment and at the final visit.
2：Sample Selection and Data Sources:
Patients with treatment-na?ve acute ME of 1- to 4-months duration secondary to central RVO (CRVO, 15 eyes) or BRVO (42 eyes) were studied.
3：List of Experimental Equipment and Materials:
Spectral-domain OCT (Spectralis, Heidelberg Engineering, Heidelberg, Germany), Microperimetry 1 (MP1, Nidek, Gamagori, Japan).
4：Experimental Procedures and Operational Workflow:
Standard ophthalmic examinations before, 1, 3, and 6 months after the injections and at the final visit.
5：Data Analysis Methods:
Repeated-measures analysis of variance (ANOVA) with Greenhouse-Geisser corrections was used to determine the significance of the changes in the BCVA, retinal sensitivity, CRT, and MV. The Bonferroni test was used for the post hoc analysis.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
